Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MSLuisa María Villar, José C. Álvarez‐Cermeño, María C. Sádaba et al.|Journal of Clinical Investigation|2005Cited by 257
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MSJosé Ignacio Fernández-Velasco, Luisa María Villar, José Meca-Lallana et al.|Neurology Neuroimmunology & Neuroinflammation|2021Cited by 65
Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple SclerosisCarmen Picón, Luisa María Villar, Amalia Tejeda Velarde et al.|Frontiers in Immunology|2021Cited by 28
Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With AlemtuzumabPaulette Esperanza Walo-Delgado, Luisa María Villar, Enric Monreal et al.|Frontiers in Immunology|2021Cited by 7
B-lymphocyte-guided retreatment contributes to establish good effectiveness and safety profile in MS patients treated with rituximabJuan Luis Chico‐García, Luisa María Villar, Fernando Rodríguez‐Jorge et al.|Multiple Sclerosis and Related Disorders|2022Cited by 6